Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 21, 2019
Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that members of management ...
February 21, 2019
DURECT Corporation to Participate in the Berenberg NASH Day
CUPERTINO, Calif., Feb. 21, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will ...
February 21, 2019
Genocea to Host Quarterly Corporate Update Conference Call & Webcast on February 28 at 9:00 am ET
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host ...
February 21, 2019
Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
EMERYVILLE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report ...
February 21, 2019
HTG Molecular to Present Corporate Overview at the Cowen & Company 39th Annual Health Care Conference
TUCSON, Ariz., Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, ...
February 21, 2019
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
NEWARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
February 21, 2019
Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
February 21, 2019
Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
February 21, 2019
Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
SAN DIEGO, Feb. 21, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present ...
February 21, 2019
Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Feb. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink ...
February 21, 2019
iCAD to Showcase ProFound AI™ Solution for Digital Breast Tomosynthesis at ECR 2019
NASHUA, N.H., Feb. 21, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc.(ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it ...
February 21, 2019
Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
Daix (France) February 21st, 2019 - Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
February 21, 2019
Celyad Announces February and March 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
February 21, 2019
TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 21, 2019
HTG Molecular Diagnostics to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on Thursday, March 7
TUCSON, Ariz., Feb. 21, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a life science company whose mission is to advance precision medicine, today ...
February 21, 2019
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
SANTA MONICA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today ...
February 21, 2019
Celyad Announces February and March 2019 Investor Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
February 20, 2019
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease
LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
February 20, 2019
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions
HAIFA, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today ...
February 20, 2019
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
Page 10 of 138